使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Welcome to the STAAR Surgical second-quarter 2026 results conference call and webcast.
歡迎收聽 STAAR Surgical 2026 年第二季財報電話會議與網路直播。
(Operator Instructions)
(接線員指示)
Please note this event is being recorded. I would now like to turn the conference over to Connie Johnson, Director of Investor Relations.
請注意,本活動將被錄音。現在我想將會議交給投資人關係總監 Connie Johnson。
Connie Johnson - Director, Investor Relations
Connie Johnson - Director, Investor Relations
Thank you, operator. Good afternoon and thank you for joining us. On the call today are Warren Foust, President and Chief Executive Officer of STAAR Surgical, and Deborah Andrews, Executive Vice President, and Chief Financial Officer of STAAR Surgical.
謝謝,接線員。各位下午好,感謝各位加入我們今天的會議。今天與會者包括 STAAR Surgical 總裁兼執行長 Warren Foust,以及 STAAR Surgical 執行副總裁兼財務長 Deborah Andrews。
Earlier today, we reported our second-quarter 2026 results via a press release in Form 8-K. We posted our results, release, and shareholder letter to our investor website at investors.staar.com. Today's call is scheduled for one hour and will include Q&A for publishing analysts. Webcast participants can also send questions for today's Q&A session to ir@staar.com.
今天稍早,我們已透過 8-K 表格的新聞稿公布 2026 年第二季業績。我們已將業績、新聞稿與致股東信函發布於投資人網站 investors.staar.com。今天的電話會議預計一小時,並包含提供給發佈研究報告之分析師的問答環節。收看網路直播的與會者也可將問題寄至 ir@staar.com,以供今日問答時段使用。
Before we get started, I want to remind you that during today's discussion, we will be making forward-looking statements. Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied by such forward-looking statements. I encourage you to read the disclosures in today's release, as well as on our filings with the SEC. Except as required by law, STAAR assumes no obligation to update these forward-looking statements to reflect future events or actual outcomes.
在開始之前,我想提醒各位,今天的討論將包含前瞻性陳述。前瞻性陳述受風險與不確定性影響,可能導致實際結果與該等前瞻性陳述所明示或暗示者有重大差異。我鼓勵各位閱讀今日新聞稿中的揭露內容,以及我們向美國證券交易委員會(SEC)提交之文件。除法律要求外,STAAR 不承擔更新這些前瞻性陳述以反映未來事件或實際結果的義務。
In addition, during today's discussion, we will reference certain non-GAAP financial measures including adjusted EBITDA and constant currency sales. Please refer to today's release for definitions and reconciliations of non-GAAP metrics. For brevity, unless otherwise specified, all comparisons on today's call will be on a year-over-year basis versus the relevant period.
此外,在今天的討論中,我們將提及若干非 GAAP 財務衡量指標,包括調整後 EBITDA 與固定匯率銷售額。請參閱今日新聞稿,以了解非 GAAP 指標的定義與調節表。為求簡潔,除非另有說明,今天電話會議中的所有比較皆為與相關期間之去年同期相比。
Finally, a quick reminder. We intend to use our website as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Such disclosures will be included on our website in the investor relations section. Accordingly, investors should monitor our investor website in addition to following our press releases, SEC filings, and public conference calls and webcasts.
最後,快速提醒一下。我們打算使用公司網站作為揭露重大未公開資訊的方式,並用以遵循《公平揭露規則》(Regulation FD)下的揭露義務。此類揭露將發布於我們網站的投資人關係專區。因此,投資人除關注我們的新聞稿、SEC 申報文件以及公開電話會議與網路直播外,也應持續留意我們的投資人網站。
And with that, I would like to turn the presentation over to our President and CEO, Warren Foust. Warren?
接下來,我想把簡報交給我們的總裁兼執行長 Warren Foust。Warren?
Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer
Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer
Good afternoon, everyone, and thank you for joining us. Six months ago, Deborah and I stepped into our roles as interim co-CEOs. Looking back now, I am struck by how much we accomplished together. We navigated uncertainty and challenges and leaned into significant opportunities. And today, we are proud to report the strongest first half revenue performance in STAAR's history.
各位下午好,感謝各位加入我們。六個月前,Deborah 和我接任臨時共同執行長的職務。回顧至今,我對我們共同完成的成果感到印象深刻。我們在不確定性與挑戰中前行,同時把握了重要機會。今天,我們很自豪地報告:我們創下 STAAR 歷史上最強勁的上半年營收表現。
That includes the launch of EVO Plus in China, which fuelled market share gains and drove both year-over-year and sequential growth in the region, back-to-back record quarters in the US, and a return to profitability and free cash flow generation across the business. These results reflect the focus, resilience, and execution of teams across the company, and that is a milestone worth celebrating.
其中包括在中國推出 EVO Plus,帶動市占率提升,並推動該地區年增與季增成長;美國連續兩季創下單季新高;以及公司整體恢復獲利並重新產生自由現金流。這些成果反映了全公司團隊的專注、韌性與執行力,這是一個值得慶祝的里程碑。
Through it all, it's been a tremendous experience, one that I'm grateful for. As we move forward, I'm proud to do so as President and Chief Executive Officer. I thank the Board for their confidence and each of you for your continued support. I want to take a moment to recognize and thank Deborah Andrews.
一路走來,這是一段非常難得的經驗,我心懷感激。展望未來,我很榮幸以總裁兼執行長的身分繼續前進。我感謝董事會對我的信任,也感謝各位持續的支持。我也想花點時間表揚並感謝 Deborah Andrews。
Over the past six months, Deborah has been an extraordinary partner, steady, wise, and tireless in her commitment to STAAR. Her clarity and focus on financial discipline, culture, and strategy have profoundly benefited this company. I'm thrilled that she continues as Chief Financial Officer and is doing so now as an Executive Vice President. I could not ask for a better partner as we lead our company forward.
過去六個月,Deborah 一直是卓越的夥伴,穩健、睿智,並以不懈的投入致力於 STAAR。她在財務紀律、企業文化與策略上的清晰與專注,為公司帶來深遠助益。我很高興她將繼續擔任財務長,並且現在以執行副總裁的職銜履任。在帶領公司向前的路上,我無法想像有比她更好的夥伴。
Now, let's talk about the quarter, which was a strong one. Our shareholder letter published today covers our second-quarter results, regional performance, ERP implementation, and long-term priorities in detail. Rather than repeat all of that here, I want to focus on the three priorities that we laid out nearly six months ago.
接下來談談本季表現,這是一個強勁的季度。我們今天發布的致股東信函,已就第二季業績、各區域表現、ERP 導入,以及長期優先事項提供詳細說明。我不在此重複所有內容,而是聚焦於我們在近六個月前提出的三項優先事項。
Revenue growth, profit expansion, and innovation acceleration. In the second-quarter, we advanced all three, and I'd like to walk you through where we stand. Starting with revenue growth, the second-quarter was a strong revenue quarter. Net sales were $93.5 million, up 111% year over year. We delivered sequential growth in China, double-digit growth in the Americas, and double-digit growth in EMEA, excluding the Middle East.
營收成長、獲利擴張,以及加速創新。在第二季,我們三項皆有推進,我想帶各位了解目前進展。先從營收成長開始,第二季是營收表現強勁的一季。淨銷售額為 9,350 萬美元,年增 111%。我們在中國實現季增;美洲地區達成雙位數成長;EMEA(歐洲、中東及非洲)在排除中東後亦達成雙位數成長。
Deborah will take you through the details a little later, but the headline is clear. This business is performing. An important item I want to flag for your modelling. Our third-quarter of 2025 results included the recognition of $25.9 million related to the 2024 order. On a consolidated basis, third-quarter 2025 net sales were $94.7 million. Excluding that item, though, the comparable total base is $68.8 million. That revenue from the 2024 order will not repeat, and we encourage you to use the adjusted base when evaluating third-quarter 2026 year-over-year results. fourth-quarter comparisons are unaffected. fourth-quarter 2025 net sales were $57.8 million.
Deborah 稍後會帶各位看更細部的內容,但重點很清楚:這項業務正在展現良好表現。我想提醒各位在建模時注意一個重要事項。我們 2025 年第三季的業績包含認列與 2024 年訂單相關的 2,590 萬美元。以合併基礎計算,2025 年第三季淨銷售額為 9,470 萬美元。但若排除該項目,可比較的總基期為 6,880 萬美元。來自 2024 年訂單的該筆營收不會重複發生,我們建議各位在評估 2026 年第三季年增表現時使用調整後基期。第四季的比較不受影響。2025 年第四季淨銷售額為 5,780 萬美元。
Now on China, I'm proud of our market share gains and of our expanding EVO Plus launch. China remains critical to our success in an area where we have a compelling opportunity ahead. In the quarter, China grew sequentially supported by increased adoption of EVO Plus, and importantly, we saw no evidence of inventory build at distributors or hospitals reinforcing that our growth is being driven by demand.
接著談中國,我為我們的市占率提升以及 EVO Plus 持續擴大的上市推進感到自豪。中國仍是我們成功的關鍵市場之一,我們在此擁有極具吸引力的未來機會。本季中國業績呈現季增,主要受 EVO Plus 採用率提升所支持;更重要的是,我們未看到經銷商或醫院出現庫存堆積的跡象,這也強化了我們的成長是由需求所驅動。
The broader refractive market remains uneven. Recent industry commentary reinforces the view that procedures remain pressured in parts of China and APAC. Against that backdrop, STAAR's performance supports our belief that EVO is gaining market share. We're definitely getting a lift from the EVO Plus rollout, but more than that, we're seeing patients and surgeons really leaning into the benefits of lens-based surgery.
整體屈光市場仍呈現不均衡。近期產業評論再次印證:在中國與亞太地區(APAC)的部分市場,手術量仍承受壓力。在此背景下,STAAR 的表現支持我們的看法:EVO 正在提升市占率。EVO Plus 的推廣確實帶來助力,但更重要的是,我們看到患者與醫師正更積極採納以晶體為基礎的手術所帶來的效益。
People like that EVO is reversible and doesn't require removing corneal tissue, and that's a big differentiator as laser-based procedures continue to struggle in many markets around the world. We also want to provide more clarity on China's seasonality. As discussed in our shareholder letter, the quarterly pattern in China has evolved. The first and second-quarters are emerging as our strongest revenue quarters, supported by Chinese New Year, a shift forward of military recruitment-related procedures, and summer demand.
大家喜歡 EVO 的可逆性,且不需要移除角膜組織;在全球許多市場雷射手術仍持續面臨挑戰之際,這是一項重要差異化優勢。我們也希望就中國的季節性提供更清楚的說明。如同我們在致股東信函中所討論,中國的季度型態已經演變。第一季與第二季正逐漸成為我們最強的營收季度,主要受農曆新年、與徵兵相關手術時點前移,以及暑期需求所支撐。
While the third-quarter revenue is expected to be moderately lower than the second-quarter due to shifts in seasonality, excluding the one-time order of $25.9 million booked in the third-quarter of 2025, we expect year-over-year growth. As is typical, the fourth-quarter will remain seasonally softer than the first three quarters, but we are still planning for year-over-year growth. Outside China, we continue to see strong revenue contributions in key markets such as Japan and Korea, as well as double-digit growth in the US, the Americas broadly, and excluding the Middle East and EMEA as well.
雖然由於季節性變化,預期第三季營收將較第二季略為下降,但若排除 2025 年第三季入帳的一次性 2,590 萬美元訂單,我們預期仍可實現年增成長。如同以往,第四季的季節性仍將較前三季偏弱,但我們仍規劃達成年增成長。在中國以外,我們持續在日本、韓國等關鍵市場看到強勁的營收貢獻;同時,美國、美洲整體,以及同樣排除中東後的 EMEA 也都維持雙位數成長。
We also see compelling long-term opportunities in many other markets around the globe. In the Americas, growth was led by another greater than $6 million quarter in the US, our second consecutive quarter at that level. The US market remains underpenetrated, and we continue to see opportunity to grow EVO sales and continue to take market share as practices look for differentiated, lens-based refractive alternatives to laser vision correction as demand for laser procedures continues to decline.
我們也在全球許多其他市場看到具吸引力的長期機會。在美洲地區,成長主要由美國市場帶動,本季在美國再度達成單季超過600萬美元的表現,這也是我們連續第二季達到該水準。美國市場的滲透率仍偏低,我們持續看到EVO銷售成長的機會,並在雷射視力矯正需求持續下滑之際,診所尋求具差異化、以晶體為基礎的屈光替代方案時,持續擴大市占。
In APAC outside of China, Japan remains an important market where EVO has strong category awareness, is a strong market leader, and has sustainable long-term potential. We continue to see solid underlying demand in Japan, bolstered by direct-to-consumer awareness initiatives launched in November of 2025.
在中國以外的亞太地區,日本仍是重要市場;EVO在該市場具備強勁的品類認知度、是明顯的市場領導者,並擁有可持續的長期潛力。我們在日本持續看到穩健的基本需求,並受惠於我們於2025年11月推出的直接面向消費者(DTC)認知推廣活動所帶動。
Unit volume rose 14%, though currency headwinds damaged the market and reported sales growth, which came in at 2%. Across the broader region, market dynamics vary, and we are being disciplined about where we invest. Excluding the Middle East, the region grew double digits, reflecting solid underlying demand across much of the region.
出貨量成長14%,但匯率逆風影響市場表現與報告銷售成長,報告銷售成長率為2%。在更廣泛的區域內,各市場動態不一,我們在投資布局上保持紀律。若排除中東,該區域呈現雙位數成長,反映區內多數市場的基本需求穩健。
Across all regions, our approach is consistent. Invest where we see the clearest returns and support surgeons and patients through service, training, and education. While we continue driving the global shift from laser-based to lens-based refractive surgery, we are also working to increase our product availability in order to satisfy the accelerating global demand that has outpaced our supply chain projections.
在所有地區,我們的策略一致。在回報最明確之處投入資源,並透過服務、訓練與教育來支持醫師與患者。在我們持續推動全球屈光手術由雷射為主轉向以晶體為主的同時,也正致力提升產品供應可得性,以滿足加速成長、且已超出我們供應鏈預測的全球需求。
The second area is profit expansion. In the second-quarter, we demonstrated meaningful progress in expanding profitability. We grew gross profit and net income compared with both the prior year quarter and the first-quarter. These improvements resulted in significant cash flow generation, increasing cash from $163.9 million at the end of the first-quarter to $181.5 million at the end of the second-quarter.
第二個重點是獲利擴張。在第二季,我們在提升獲利能力方面展現了實質進展。相較去年同期與第一季,我們的毛利與淨利均有所成長。這些改善帶來顯著的現金流入,使現金餘額由第一季末的1.639億美元增加至第二季末的1.815億美元。
This progress reflects the strength of our business model and the financial discipline that Deborah and the team had brought to the organization. The result is a company with strong gross margins, a strong balance sheet, no debt, an increasing cash balance, and the flexibility to invest in the business where it matters, commercial execution, customer support, product availability, innovation, and the systems that help us scale.
這項進展反映我們商業模式的強韌性,以及Deborah與團隊為組織帶來的財務紀律。其結果是一家擁有強勁毛利率、穩健資產負債表、零負債、現金餘額持續增加,並具備彈性可在關鍵領域投資的公司,包括商業執行、客戶支援、產品供應可得性、創新,以及協助我們擴張的系統。
Our ERP implementation demanded significant energy and focus across the organization in the quarter. Teams delivered. We continued to sell EVO lenses. We provided support for our customers and achieved strong results. The ERP system is now live and we are actively optimizing the system in the third-quarter. This is not just an operational upgrade.
本季ERP導入在全公司範圍內需要投入大量精力與專注。各團隊交出了成果。我們持續銷售EVO晶體。我們為客戶提供支援並取得強勁表現。ERP系統現已上線,我們正在第三季積極進行系統優化。這不僅僅是一次營運升級。
It is a foundational investment that improves visibility across our business and positions us to scale more effectively and efficiently as we grow. With the ERP system in place, we are also beginning to build towards artificial intelligence enabled capabilities that will improve how we operate over time.
這是一項基礎性投資,可提升我們對整體業務的可視性,並在成長過程中讓我們能更有效率、更有效地擴張。在ERP系統到位後,我們也開始朝向建置具人工智慧(AI)賦能的能力邁進,長期將改善我們的營運方式。
The third area, innovation acceleration, is the one that I am most excited about. EVO is a genuinely differentiated product built on our proprietary Collamer material. It is a lens-based procedure that preserves the cornea, is removable by a surgeon, and addresses a broad range of myopia and astigmatism. While our progress is significant and exciting, accelerating, our global share of the refractive market remains far below what we believe is possible. That gap is our opportunity. Capturing it requires moving beyond a single product mindset.
第三個重點——加速創新——是我最感到振奮的部分。EVO是一項真正具差異化的產品,建立在我們專有的Collamer材料之上。這是一種以晶體為基礎的手術,可保留角膜、可由醫師移除,並可涵蓋廣泛的近視與散光度數範圍。儘管我們的進展顯著且令人振奮、並正在加速,但我們在全球屈光市場的市占仍遠低於我們認為可能達到的水準。這個差距就是我們的機會。要把握這個機會,需要超越單一產品的思維。
EVO, powered by Collamer, is our foundation, but we have the opportunity to build a broader platform and a more diversified product organization supported by a disciplined innovation roadmap, structured product development, clear milestones, and a stronger execution accountability. Our R&D team, including our advanced research group, is working hard against these objectives and is actively preparing for first-in-human studies on our next-generation product.
以Collamer為核心的EVO是我們的基礎,但我們有機會打造更廣泛的平台,以及更為多元化的產品組合;並以具紀律的創新藍圖、結構化的產品開發、清晰的里程碑與更強的執行問責來支撐。我們的研發團隊(包含先進研究團隊)正針對這些目標全力推進,並積極準備下一代產品的首次人體試驗(first-in-human studies)。
To further support our efforts, we will soon be hiring a chief technology officer to drive STAAR's innovation agenda. I have personally led this search with the support from trusted advisors and our board. And I'll say this, this process has only deepened my conviction about STAAR's long-term potential. I'm excited to share more in the coming weeks. This is the next chapter of STAAR, Grounded and Differentiated Technology, Disciplined Execution and Sustainable Long-Term Value Creation.
為進一步支持我們的工作,我們將很快聘任一位技術長(CTO)來推動STAAR的創新議程。在值得信賴的顧問與董事會支持下,我親自領導了這項招募。我想說的是,這個過程只讓我對STAAR的長期潛力更加篤定。我很期待在未來幾週分享更多資訊。這是STAAR的下一篇章:以扎實且具差異化的技術為根基、以紀律化執行為核心,並創造可持續的長期價值。
With that, I'll turn the call over to Deborah to walk through the financials in more detail.
接下來,我把電話會議交給Deborah,請她更詳細說明財務表現。
Deborah Andrews - Interim Co-Chief Executive Officer, Chief Financial Officer
Deborah Andrews - Interim Co-Chief Executive Officer, Chief Financial Officer
Thank you, Warren. I'll provide a brief financial summary and then we'll move to Q&A. second-quarter net sales were $93.5 million compared to $44.3 million in the prior year quarter, which, as a reminder, was impacted by minimal China shipments while distributors worked through excess inventory.
謝謝你,Warren。我將提供簡要的財務摘要,接著我們會進入問答。第二季淨銷售額為9,350萬美元,去年同期為4,430萬美元;提醒一下,去年同期因經銷商在消化過剩庫存期間,中國出貨量極少而受到影響。
Excluding China, net sales were $41.2 million, up 6% year over year. Initially, the quarter was generally consistent with the preliminary net sales update we provided in July. APAC net sales increased 189% year-over-year. Excluding China, net sales were up 7% year-over-year. China net sales increased 100 %-plus and grew 10% sequentially to $52.3 million.
若排除中國,淨銷售額為4,120萬美元,年增6%。整體而言,本季表現大致符合我們在7月提供的初步淨銷售更新。亞太地區淨銷售額年增189%。若排除中國,淨銷售額年增7%。中國淨銷售額成長超過100%,且較前一季成長10%至5,230萬美元。
In Japan, unit volume rose 14%, though currency headwinds dampened reported sales growth, which came in at 2%. The Americas grew 12% year-over-year, and the US delivered another approximately $6 million quarter. EMEA has declined 1%, resulting from the continued conflicts in the Middle East. Excluding the Middle East, EMEA also grew 12% year over year.
在日本,出貨量成長14%,但匯率逆風抑制了報告銷售成長,報告銷售成長率為2%。美洲地區年增12%,美國市場再度貢獻約600萬美元的單季表現。EMEA年減1%,主要因中東地區持續衝突所致。若排除中東,EMEA亦年增12%。
Gross margin was 74.5% compared to 74% in the prior year quarter. The improvement reflected lower Switzerland ramp-up costs, reduced advanced manufacturing expenses, inventory provisions and lower freight and other costs of sales as a percentage of sales, partially offset by higher per unit manufacturing costs related to lower production volumes in 2025. Gross margin was also negatively impacted by China tariffs on US manufactured product.
毛利率為74.5%,去年同期為74%。毛利率改善反映瑞士產能爬坡成本降低、先進製造費用下降、存貨提列減少,以及運費與其他銷貨成本占銷售比重下降;但部分被2025年較低產量導致的單位製造成本上升所抵銷。毛利率亦受到中國對美國製造產品課徵關稅的不利影響。
Margins will continue to be impacted by tariffs until 100% of products shipped to China are manufactured in Switzerland, which should happen by the end of 2026. Total operating expenses were $59.6 million compared to $62.8 million in the prior year quarter. Excluding $5.2 million in restructuring and merger related costs from the prior year period, operating expenses increased approximately 3.7% year over year. Included within operating expenses were $1.2 million in marketing severance and $1.7 million in ERP consulting.
在運往中國的產品100%改由瑞士製造之前,關稅將持續影響毛利率;此目標預計於2026年底前達成。總營業費用為5,960萬美元,去年同期為6,280萬美元。若排除去年同期5,200萬美元的重整與併購相關成本,營業費用約年增3.7%。營業費用中包含120萬美元的行銷遣散費,以及170萬美元的ERP顧問費用。
We don't expect the severance to repeat and expect the ERP consulting expense to decline significantly beginning in the fourth-quarter. Depreciation expense related to ERP systems was $1.1 million. We continue to manage toward our 2026 spending target of $225 million, though we may choose to make targeted investments that could result in marginally higher spending should the opportunity arise.
我們預期遣散費不會重複發生,並預期ERP顧問費用自第四季起將顯著下降。與ERP系統相關的折舊費用為110萬美元。我們仍以2026年2.25億美元的支出目標為管理方向,但若出現機會,我們可能選擇進行具針對性的投資,導致支出略為提高。
Net income was $8.1 million, or $0.16 per diluted share, compared to a net loss of $16.8 million, or $0.34 per diluted share, in the prior year quarter. Adjusted EBITDA was $20 million, or $0.39 per diluted share, compared to an adjusted EBITDA loss of $14.8 million or $0.30 per diluted share in the prior year quarter. We ended the quarter with $181.5 million in cash, cash equivalents, and investments available for sale, up from $163.9 million at the end of the first-quarter, and we continue to have no debt.
淨利為 810 萬美元,或每股稀釋後盈餘 0.16 美元,相較於去年同期為淨損 1,680 萬美元,或每股稀釋後虧損 0.34 美元。調整後 EBITDA 為 2,000 萬美元,或每股稀釋後 0.39 美元,相較於去年同期調整後 EBITDA 虧損 1,480 萬美元或每股稀釋後虧損 0.30 美元。本季末我們持有現金、約當現金及可供出售投資合計 1.815 億美元,高於第一季末的 1.639 億美元,且我們仍然沒有負債。
The company currently expects to generate significant free cash flow in the half of the year, ending 2026 with well over $200 million in cash. Overall, the second-quarter reflected meaningful improvement in profitability, cash generation, and operating leverage. Our focus remains on maintaining financial discipline, advancing new product development, and investing selectively in the opportunities with the clearest return potential.
公司目前預期在今年下半年產生可觀的自由現金流,並在 2026 年底持有遠超過 2 億美元的現金。整體而言,第二季在獲利能力、現金創造與營運槓桿方面反映出顯著改善。我們的重點仍是維持財務紀律、推進新產品開發,並在回報潛力最明確的機會上選擇性投資。
With that, I'll turn it back to Warren.
接下來我把時間交還給 Warren。
Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer
Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer
Thank you, Deborah. Stepping back, the second-quarter was a strong quarter that rounded out the best first half-year revenue performance in STAAR history. This is yet another step forward for STAAR. We grew revenue, expanded gross margins, generated net income, and built cash. And we have much to be proud of, growing EVO Plus adoption in China, back-to-back record quarters in the US, a successful ERP implementation, and early progress in organizing our product pipeline with an eye toward the mid- and long-term future.
謝謝你,Deborah。退一步看,第二季表現強勁,讓 STAAR 歷史上最佳的上半年營收表現更臻完整。這是 STAAR 再向前邁進的一步。我們實現營收成長、擴大毛利率、創造淨利並累積現金。我們也有許多值得自豪之處,包括在中國推動 EVO Plus 採用率提升、美國連續兩季創下紀錄、成功導入 ERP,以及在以中長期未來為目標的前提下,於產品管線組織方面取得初步進展。
Our strategy is clear, our team is focused and performing, and our long-term opportunity remains as compelling as ever. With more than 4 million lenses sold, 85 countries served, and 32 years of proven Collamer safety and efficacy in a world that is becoming more myopic every year. Now, our focus is to build on this momentum. Revenue growth, expanding profitability, and advancing innovation.
我們的策略清晰、團隊專注且表現出色,而我們的長期機會依然一如既往地引人注目。我們已售出超過 400 萬片晶體、服務 85 個國家,並在一個每年都更加近視化的世界中,擁有 32 年經驗證的 Collamer 安全性與有效性。現在,我們的重點是延續這股動能。推動營收成長、擴大獲利能力,並推進創新。
Deborah and I are aligned with our board and management team as we focused on long-term value creation through clear priorities and operating discipline. Thank you for your continued support.
Deborah 與我與董事會及管理團隊保持一致,專注於透過明確的優先事項與營運紀律來創造長期價值。感謝各位持續的支持。
With that, operator, we are now ready to take questions.
接下來,接線員,我們現在準備開始回答問題。
Operator
Operator
(Operator Instructions)
(接線員指示)
John Young, Canaccord.
John Young,Canaccord。
John Young - Equity Analyst
John Young - Equity Analyst
I want to touch on Q3 and just maybe understand how you're going to level set investors, just given the comps and the one-timers that he called out. So using that adjusted number of $68.8 million that was in the press release and that he spoke about, you know, consensus currently sits at $80.9 million going into this print, so about 17.5% year-over-year growth from that figure you provided. Are you comfortable with the consensus number today? And what's a good way to think of the Q3 growth algorithm? If you're not comfortable about that number, how should we think about growth overall for the quarter?
我想談一下第三季,並了解你們打算如何幫投資人重新校準預期,考量到可比基期以及他提到的一次性因素。因此,以新聞稿中提到、他也談到的 6,880 萬美元調整後數字來看,目前市場共識在這次公布前為 8,090 萬美元,換算成你提供的數字約為年增 17.5%。你們目前對這個共識數字感到放心嗎?以及,思考第三季成長的「算法」有什麼好的方式?如果你們對那個數字不放心,我們應該如何看待本季整體成長?
Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer
Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer
Yes, hey John, great question. Nice to hear from you, and I'll make some comments and then invite Deborah to join. Look, we don't comment on consensus numbers generally. What I would say is we tried to give a little bit of a bridge to how you think about Q3 and Q4. We wanted to be clear that you needed to take the 2024 order out of the Q1 order so that you could have an appropriate base. We intend to grow off of that number. In fact, we're planning to grow on Q4 as well. That's what we would say as far as how to think about it.
是的,嗨 John,問題很好。很高興聽到你的聲音,我先說幾點,然後也請 Deborah 一起補充。你看,我們一般不評論市場共識數字。但我想說的是,我們試著提供一些銜接,讓大家知道該如何看待第三季與第四季。我們希望說清楚,你需要把 2024 年的訂單從第一季訂單中扣除,這樣才能得到合適的基期。我們打算在那個數字的基礎上成長。事實上,我們也規劃第四季同樣要成長。就如何思考而言,我們大概會這樣說。
I think the primary driver of the success so far, clearly China has come back for us. We recognize that the market is somewhat muted. You hear that in some of the commentary about other companies that are reporting, but we believe we have a nice advantage with EVO Plus launching in that market. We're clearly taking share relative to our competitors. And then we're still putting up a nice performance around the rest of the world, even in the face of some external challenges.
我認為目前成功的主要驅動因素,顯然是中國市場對我們而言已經回溫。我們也認知到整體市場相對偏淡。你會在其他正在公布業績的公司評論中聽到這點,但我們相信,隨著 EVO Plus 在該市場上市,我們具備不錯的優勢。相較競爭對手,我們顯然正在取得市占。此外,即便面臨一些外部挑戰,我們在全球其他地區仍繳出不錯的表現。
John Young - Equity Analyst
John Young - Equity Analyst
Okay, great. And then maybe just as a quick follow-up then, any of this color on where EVO Plus is today as a share of China volume versus your initial expectations at launch? And then maybe how could we think about the price versus unit benefit in Q3 to China?
好的,很棒。那再快速追問一下:就 EVO Plus 目前在中國的量占比而言,相較於上市初期你們的預期,現在大概在哪裡?另外,我們在第三季該如何看待中國市場的價格效益相對於出貨量效益?
Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer
Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer
You bet. Yes, it's a good one. Look, we're excited about what's happened with EVO Plus. Candidly, it's outstripped our supply capabilities based on the demand. It's higher than what we anticipated it would be. Certainly, we saw that in the first-quarter, and second-quarter was no different. So, even in other markets around the world, we're now working to try and sort through scaling up supply to be able to reach the demand.
當然。是的,這個問題很好。你看,我們對 EVO Plus 的進展感到很振奮。坦白說,需求已經超出我們的供應能力。它的需求高於我們原先預期。第一季我們就看到這點,第二季也沒有不同。因此,即便在全球其他市場,我們現在也在努力處理擴大供應規模,以滿足需求。
And so that speaks to EVO Plus has done better in China than expected. As far as the percent penetration of it, look, by the time we exited the quarter, it's probably close to a third of the units. And so we feel that's pretty strong, and it beats what we expected when we started. So, you know, how you think about it going forward from a price standpoint, we're still taking a considerable premium. Our customers and seemingly their patients have not balked at that premium. And so we expect that to continue at least into the near term. And then we'll see what next year brings.
這也說明 EVO Plus 在中國的表現優於預期。至於滲透率比例,你看,到本季結束時,它大概接近三分之一的出貨量。我們覺得這相當強勁,也超出我們一開始的預期。所以,從價格角度來看,往後你可以這樣思考:我們仍然維持相當可觀的溢價。我們的客戶以及看起來他們的病患並未對這個溢價卻步。因此我們預期至少在短期內會持續如此。至於明年會如何,我們再觀察。
Operator
Operator
Tom Stephan, Stifel.
Tom Stephan,Stifel。
Thomas Stephan - Analyst
Thomas Stephan - Analyst
I want to start off with China and sort of thinking more intermediate to long term. Comp's weird this year when the street looks at numbers, but you're seeing obviously underlying volume growth. obviously have a good sense on price and mix. So not asking for guidance or anything, Warren, but if we think out to 2027 on a full year basis, and that obviously strips out any quarter to quarter seasonality questions, like as we sit here today, what do you view as the general range of call it normalized year-over-year China growth for STAAR, and then I'll have a follow-up.
我想先從中國談起,並以較中期到長期的角度來思考。今年在華爾街看數字時,可比基期有點怪,但你們顯然看到基本面的出貨量成長,也對價格與組合有很好的掌握。所以我不是在要指引或什麼,Warren,但如果我們把時間拉到 2027 年、以全年為基礎來看,這也會排除任何季度間季節性問題;以我們今天所處的位置,你認為 STAAR 在中國的「常態化」年增成長率大致區間會是多少?我之後還有一個追問。
Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer
Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer
Yes, thanks, Tom. Appreciate the comments. And look, I love that you said you're thinking intermediate to long term. That's what we want. We're focused on building the long term, not just from the revenue standpoint, but the infrastructure investments that we're making in the organization, the preparations we're making behind the scenes from a portfolio standpoint. We are intending to operate this business into the long term. So thanks for that mindset.
是的,謝謝你,Tom。感謝你的評論。而且你提到你在思考中期到長期,我很喜歡。這正是我們想要的。我們專注於打造長期發展,不僅是營收層面,也包括我們在組織上所做的基礎建設投資,以及我們在產品組合層面於幕後所做的準備。我們打算長期經營這項業務。所以謝謝你有這樣的思維。
You said it, look, aside from the nuance of us taking out the $25.9 million from the Q3 base, now we're going to be back to what we call clean quarters. We had clean quarters already this year, and you've seen growth better than market in China, and you've seen us continue to deliver in markets elsewhere around the world. And so I have no reason to believe that's going to change in China.
你說得沒錯。你看,除了我們把 2,590 萬美元從第三季基期中剔除這個細節之外,接下來我們會回到我們所說的「乾淨季度」。今年我們已經有乾淨季度,你也看到我們在中國的成長優於市場,同時也看到我們在全球其他市場持續交出成果。因此,我沒有理由相信在中國會有所改變。
Our thinking is that as that market, which we think is probably mid to single digits right now from a refractive market standpoint, pulled down a little bit by lasers that are struggling, but it's offset by improvements that are happening, largely because of price with EVO Plus and then V4c halo effect that's happening when patients go in looking for V5 and either don't get it because it's slightly higher price from a premium standpoint, or it's not even available because we're trying to satisfy that demand.
我們的看法是,從屈光市場的角度來看,該市場目前我們認為大概是中到個位數的成長;雖然受到表現吃力的雷射業務拖累而略有下滑,但這部分被正在發生的改善所抵銷,主要來自 EVO Plus 的價格因素,以及當病患進來尋找 V5、但因為從高端定價角度略高而未選擇,或甚至因我們正努力滿足需求而無法供應時,V4c 所帶來的光環效應。
So we think that feels like a tailwind as we go into next year, but it's But not only that, we did try and give some more guidance, not formal guidance, but some guidance around what the shape of the quarters look like in China. Clearly Q1 and Q2 have now moved in the last couple of years to be seasonally our highest quarters. Q3 is still strong, but it's typically going to be less than what Q1 and Q2 are, and Q4 will be a softer quarter from a total revenue standpoint. But again, we're planning growth in both of those quarters, notwithstanding the $25.9 million that we've talked about extensively. I hope that makes sense.
因此我們認為,隨著我們進入明年,這感覺像是一股順風;但不僅如此,我們也嘗試就中國各季度的走勢形狀提供更多一些指引——不是正式指引,但算是一些方向。很明顯,在過去幾年裡,第一季與第二季已經轉變為我們季節性最高的季度。第三季仍然強勁,但通常會低於第一季與第二季,而第四季從總營收角度來看會是較疲弱的一季。不過再次強調,即便考量到我們已經廣泛討論過的 2,590 萬美元,我們仍在規劃這兩個季度都要成長。希望這樣說得通。
Thomas Stephan - Analyst
Thomas Stephan - Analyst
Makes sense. Appreciate that. And I'll maybe shift a little near term. I wanted to start off long term to set this up a little better, but I'll take a stab at kind of the 3Q, 4Q cadence and focus on China here. Warren, if I got this right, I think you mentioned 3Q China revenues moderately lower than 2Q. Hopefully I heard that right. Wondering if we can put a finer point on that.
說得通。謝謝你的說明。我可能把焦點稍微拉回近期。我原本想先從長期談起,好讓脈絡更清楚,但我先試著就第三季、第四季的節奏來問,並把重點放在中國。Warren,如果我理解正確,我想你提到第三季中國營收會比第二季溫和下降。希望我聽得沒錯。想請問能否更精準一些。
And I'll ask it in the context of 3Q24 and 3Q23. China dollar declines were $10 to $15 million, roughly speaking. Aaron or Deborah, is that reasonable for 3Q26 China, particularly as EVO Plus Mix, I think, continues to provide a continued sequential headwind. And as we try to contemplate, it sounds like pretty resilient ICL, China summer high season trend. So is that down $10 to $15 million that you've seen in the past a good anchor point?
我也想在 2024 年第三季與 2023 年第三季的脈絡下來問。中國以美元計的下滑大約是 1,000 萬到 1,500 萬美元。Aaron 或 Deborah,對於 2026 年第三季的中國而言,這樣的幅度是否合理?特別是我認為 EVO Plus Mix 仍在持續帶來環比的逆風。同時我們也在思考,聽起來 ICL 在中國夏季旺季的趨勢相當有韌性。所以,過去看到的下滑 1,000 萬到 1,500 萬美元,是否可以作為一個不錯的參考基準?
Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer
Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer
Yes, that's a good one. Look, I'll start and then invite Deborah. I think it's important to remember two things. The seasonal shift has happened that I described. So Q1 and Q2, we expect to be stronger. That's borrowing partially from Q3. So it's hard for us to say, gosh, this is exactly what we think is going to happen in Q3 because one, because of that dynamic, and then two, because of what we said around having to pull some of that 2024 order out of Q3. But we still expect the underlying, I think the important piece, the underlying demand in China, it's stable.
是的,這個問題問得很好。我先回答,然後也請 Deborah 補充。我認為要記住兩件事很重要。我剛才描述的季節性轉移已經發生。因此第一季與第二季,我們預期會更強。這在某種程度上是從第三季「借」過來的。所以我們很難說,天啊,我們認為第三季一定會發生什麼,第一是因為這個動態,第二是因為我們提到過,必須把部分 2024 年的訂單從第三季拉出來。但我們仍然預期——我認為關鍵在於——中國的底層需求是穩定的。
It's not amazing. It's not as high as it was back in periods of hypergrowth, but we're taking advantage of it disproportionately because of the acceleration of share capture in our view. So I think that's how I would be thinking about it. It's hard for us to put a number on that, which is sort of stating the obvious why we have it.
它不算驚人。也不像過去高速成長時期那麼高,但我們認為,因為市占率加速取得,我們正在以不成比例的方式受益。所以我會用這樣的角度來思考。我們很難對此給出一個數字——這也算是顯而易見地說明了為什麼我們會這樣表述。
Operator
Operator
Anthony Petrone, Mizuho Americas.
Anthony Petrone,瑞穗美洲(Mizuho Americas)。
Anthony Petrone - Analyst
Anthony Petrone - Analyst
Maybe I'll pivot to the US and then come back to China. Just maybe an update on active sites and the strategy. So where are we in terms of total active sites in the US? And I know that there was sort of a go deeper penetration strategy, but also there was a push to open up new sites. maybe where are we on active sites and a recap and a refresh on the strategy between deeper penetration at the EVO live sites versus going after new accounts. And then I'll have a follow-up on China.
我可能先把話題轉到美國,之後再回到中國。想請更新一下活躍據點(active sites)以及策略。所以目前美國的活躍據點總數大概是多少?我知道之前有一個「更深度滲透」的策略,同時也有推動開拓新據點。能否談談目前活躍據點的狀況,並回顧與更新一下策略:是在既有 EVO 上線據點做更深滲透,還是去開發新客戶?然後我會再追問一個中國相關問題。
Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer
Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer
Yes, thanks Anthony. Good to hear from you. Look, what we're seeing in the US is a bit of what we're seeing around the world. Remember that only got the approval for EVO in '22. Commercial launch kind of happened in 2023 as we built up the team. And what you're seeing now is we've got hundreds and hundreds and hundreds of active sites. We're going deeper where we know we can make the biggest difference. We're focused on two key things.
好的,謝謝 Anthony。很高興聽到你的聲音。你在美國看到的情況,有點像我們在全球其他地方看到的。請記得,我們是在 2022 年才拿到 EVO 的核准。隨著我們建立團隊,商業化上市大概是在 2023 年發生。而你現在看到的是,我們已經有數百、數百、再數百個活躍據點。我們會在我們知道能帶來最大差異的地方做更深的滲透。我們聚焦在兩個關鍵點。
And it's a US discussion, but it's also one that is relevant outside of the US And that is, once we get customers clinically confident, when they use EVO, and those patients come back and they see them in the clinic, or they see the optometrist, these are happy people.
這雖然是美國的討論,但同樣也適用於美國以外的市場:一旦我們讓客戶在臨床上建立信心,當他們使用 EVO,而這些病患回診、在診所回來看他們,或是去看驗光師時,這些人都很滿意。
And so what we're seeing is the surgeons get more confident clinically and then they look for how do I make this work for me economically and that varies by whether they operate in their practice or whether they go down the street in their car to a multi-specialty ASC where they have to pay anywhere from $900 to $1,800 an eye to operate on them. That's a more challenging situation to where we have in-office suites where the doctor can go right down the hall and operate in his or her own practice. So you can see where there's opportunity sets within each one of those scenarios.
因此我們看到外科醫師在臨床上更有信心,接著他們會思考:我如何在經濟上讓這件事對我有利?這會因他們是在自家診所手術,或是開車到街角的多專科門診手術中心(ASC)而有所不同;在 ASC 手術,他們每隻眼需要支付約 900 到 1,800 美元不等的費用。相較之下,如果是診所內手術室(in-office suites),醫師可以直接走到走廊另一端,在自己的診所內替病患手術。所以你可以看到,在這兩種情境中各自都存在不同的機會組合。
We've stratified those customers. Our team is actively and aggressively going after clinically confident customers with an economic message that says, you've got revenue that's walking out of your practice because they're high diopter and someone's trying to sell them LASIK, which is declining year over year, and now again quarter over quarter. And so that's a little bit of an almost dated discussion because what's happening now is patients are asking for EVO because they're hearing more about it.
我們已經把這些客戶分層。我們的團隊正積極且強勢地鎖定那些在臨床上已建立信心的客戶,並以一個經濟面的訊息去溝通:你有營收正從你的診所流失,因為他們是高度數,而有人正試圖向他們推銷 LASIK;LASIK 的需求年減,而且現在又出現季減。不過這個討論某種程度上有點過時,因為現在正在發生的是,病患因為聽到更多相關資訊,開始主動詢問 EVO。
Younger patients and younger doctors recognize the value of a removable, reversible technology, and so they're more excited. So more of those surgeons in the US are offering EVO as one of their refractive surgery options. And so you're seeing the adoption, you're seeing less walkout revenue, and you're seeing more of the practices that we're targeting narrow the delta for the patient from a pricing standpoint. So they make it more accessible to them, and that's what we're seeing drive the adoption in the US. It's still on smaller volume that we want, but we're proud of another $6 million quarter and looking forward to continued growth.
較年輕的病患與較年輕的醫師認同可移除、可逆轉技術的價值,因此更感興趣。所以在美國,越來越多外科醫師把 EVO 作為其屈光手術選項之一。因此你會看到採用率提升、流失營收減少,也會看到我們鎖定的更多診所,從定價角度縮小病患需要負擔的差距。也就是讓病患更容易負擔,而這正是我們看到推動美國採用的因素。目前量還比我們想要的規模小,但我們對又一個 600 萬美元的季度感到自豪,並期待持續成長。
Anthony Petrone - Analyst
Anthony Petrone - Analyst
Very helpful. And China, you know, EVO Plus, just a reminder, what percent of the market does the larger lens size open up in China? And then just looking at the consignment numbers, they're up pretty substantially year over year in the queue. I was wondering how much of the China consignment sales were linked to EVO Plus.
非常有幫助。回到中國,關於 EVO Plus,提醒一下:較大鏡片尺寸在中國能開啟的市場占比大概是多少?另外再看寄售(consignment)數字,佇列中的數字年增幅相當大。我想了解,中國的寄售銷售中,有多少是與 EVO Plus 相關?
Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer
Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer
I'll let Deborah comment on the consignment sales. I'll just say as far as opening up the opportunity, look, the way we see market demand is it's unlimited. And that's not just China, that's on a global basis. The amount of refractive error on this planet is untreated and it's massive. And so we're on a journey after it. Obviously, we're constrained by some things. We're constrained by total patient in the refractive market coming in and seeking consultation.
我會讓 Deborah 來評論寄售銷售。我只想說,就開拓機會而言,你看,我們對市場需求的看法是:它是無上限的。而且不只是中國,而是全球範圍。這個星球上的屈光不正未被治療的量非常龐大。因此我們正踏上追逐這個機會的旅程。當然,我們也受到一些因素限制。我們受限於屈光市場中實際進來並尋求諮詢的患者總量。
And then as it pertains to EVO Plus in China, we're constrained a bit by inventory as we've been struggling to build enough to meet the demand in Q1 and then in Q2. I think we're getting our hands around that now, particularly as we get into the latter parts of Q3 and into Q4, we'll see some of the demand slow down just because of the dynamics of the seasonality. So that'll actually help us from a supply standpoint.
接著談到中國的 EVO Plus,我們在一定程度上受到庫存限制,因為我們一直在努力提升產能,以滿足第一季以及第二季的需求。我認為我們現在正在把這件事掌握住,特別是進入第三季後段到第四季時,因為季節性動態的關係,需求會稍微放緩。因此從供應端的角度來看,這反而會對我們有幫助。
But you're seeing, you know, There's no additional number of patients that EVO Plus opens up because EVO Plus can be used for any number of patients that EVO could be used for. It becomes a premium positioning at the account level and whether the patient has the economics to support themselves on it.
但你看到的是,EVO Plus 並不會額外開啟更多患者數,因為 EVO Plus 可用於任何 EVO 原本就能使用的患者。它更多是在客戶端(帳戶層級)的高端定位,以及患者是否具備足夠的經濟能力來負擔。
Deborah Andrews - Interim Co-Chief Executive Officer, Chief Financial Officer
Deborah Andrews - Interim Co-Chief Executive Officer, Chief Financial Officer
I guess this is Deborah. From a consignment standpoint, actually our consignments in China are way down. And that's why you're seeing increased tariff costs on the gross margin side. Because if you recall, we shipped those consignments before the increased tariffs were put into effect last year, early last year. And so now that those lenses have been used, we're shipping US product into China increasingly and they are subject to tariffs. But the overall numbers are way down in China in consignments.
我想這題由 Deborah 來回答。就寄售而言,其實我們在中國的寄售量大幅下降。這也是為什麼你會在毛利端看到關稅成本上升。因為如果你還記得,我們是在去年關稅上調生效之前(去年年初)就把那些寄售品出貨了。而現在那些鏡片已經被使用完,我們愈來愈多把美國製產品出貨到中國,而這些產品需要課徵關稅。但整體而言,中國的寄售數量確實大幅下降。
Operator
Operator
Simran Kaur, Wells Fargo.
Simran Kaur,富國銀行。
Simran Kaur - Analyst
Simran Kaur - Analyst
Warren, you know, you framed the China share gains as coming primarily from laser-based procedures. Can you just help us understand the mechanism behind that? Are you seeing more patients opt for ICL up front, or is the bigger driver surgeons expanding into ICL and converting procedures within their practices? And as domestic competition develops in the China refractive market over the next few years, how durable do you believe those share gains are?
Warren,你把中國市占提升主要歸因於雷射手術的轉換。你能否幫我們理解背後的機制?你們看到更多患者一開始就選擇 ICL,還是更主要的驅動因素是外科醫師擴展到 ICL,並在其院內把手術從原本的類型轉換過來?另外,隨著未來幾年中國屈光市場的本土競爭加劇,你認為這些市占提升有多持久?
Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer
Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer
Yes, hey, Simran. Thanks for the question. Look, I think starting with the competition, I think We're thrilled to have competition. It's just more of an admonition that the future's lens-based from a refractive surgery standpoint. You're seeing laser volumes around the world face headwinds. And is that what's happening in China? It's hard to say getting into the share discussion. believe a little bit of all of its happening. Patients are coming in asking for EVO Plus. Oftentimes, they're getting EVO Plus if they have the economics to do it and we're able to supply it.
是的,嗨 Simran。謝謝你的問題。你看,我想先從競爭談起,我們其實很高興有競爭。這更像是一種提醒:從屈光手術的角度看,未來會是以晶體(lens-based)為主。你會看到全球的雷射手術量都面臨逆風。那中國是不是也在發生同樣的事?要深入到市占討論其實很難說,但我相信各種因素都有在發生。患者會進來指名要 EVO Plus。很多時候,只要患者的經濟能力允許、而且我們供貨跟得上,他們就會選擇 EVO Plus。
And then even when they're not and if they're a candidate for V4c, we're seeing a bit of a halo effect that's happening from that standpoint. So despite the otherwise sort of modest market growth in refractive in China, we believe we're getting a bigger share of it because we're getting dollar share with EVO Plus and we're getting some unit share probably with EVO Plus and with EVO that's inviting that competition. And so, we respect it. We see it outside of China. We see it inside of China. It's not made such an impact so far. Remember, these are acrylic lenses. The advantages of STAAR for 32 years and beyond now is our material.
即便不是如此、如果他們是 V4c 的適應症,我們也看到某種光環效應(halo effect)在發生。因此,儘管中國屈光市場整體成長相對溫和,我們認為我們拿到更大的份額,因為透過 EVO Plus 我們取得了金額市占(dollar share),而且可能也透過 EVO Plus 與 EVO 取得了一些單位市占(unit share),同時也吸引了競爭進入。所以,我們尊重競爭。我們在中國以外看得到。我們在中國內部也看得到。到目前為止,它還沒有造成太大的影響。請記得,這些是壓克力材質的鏡片。STAAR 32 年以上的優勢在於我們的材料。
The EVO and EVO Plus powered by Collamer message is very real and the trust that our surgeons have for a device that they've had implanted for 30 plus years gives them great confidence, and I think it makes it more challenging for these other devices that are not made out of Collamer to compete in those markets. It doesn't mean that we have any disrespect for them, it just means they've got an uphill.
EVO 與 EVO Plus 由 Collamer 材料所驅動(powered by Collamer)的訊息非常真實;而外科醫師對一個已植入超過 30 年的器械所建立的信任,給了他們很大的信心。我認為這也讓那些不是以 Collamer 製成的其他器械,在這些市場中競爭變得更具挑戰。這不代表我們對他們有任何不尊重,只是意味著他們要走的路更艱難。
Simran Kaur - Analyst
Simran Kaur - Analyst
Got it, very helpful. And for my follow-up, you know, ex-China, I can certainly appreciate on a year-over-year basis every region grew, but if I look at the growth rates across APAC in particular, it looks like it's decelerated pretty significantly. So maybe just to help us understand what's going on in the region, And more broadly, should we think about ex-China as sort of a mid-single-digit grower going forward, or is there opportunity to re-accelerate the growth rate there?
了解了,很有幫助。那我追問一下,你知道,在不含中國(ex-China)的部分,我當然理解以年對年來看每個地區都有成長,但如果我看 APAC 尤其是各市場的成長率,看起來明顯大幅放緩。所以也許你能幫我們理解該區域發生了什麼?更廣泛地說,未來我們是否應把 ex-China 視為中個位數成長(mid-single-digit grower),還是那邊有機會讓成長率再加速?
Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer
Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer
You know, we have strong contributions from our largest markets in the region in APAC, Japan, and Korea. Japan grew substantially from a unit standpoint but faced tremendous headwinds from a currency experience from an exchange standpoint. So I think it's 13% or 14% growth even in units, and then what we faced after currency was just 2% growth.
你知道,我們在 APAC 區域最大的市場——日本與韓國——都有很強的貢獻。日本從出貨量(unit)角度看成長很顯著,但在匯率/換匯方面遭遇了非常大的逆風。所以我想,單位數大概有 13% 或 14% 的成長,但在匯率影響之後,成長就只剩 2%。
So it's modest from that perspective, but the underlying market activity is strong. And we don't have any reason to think that that's going to change. Korea is a bit of the low season for Korea. Korea's also, it's a smaller market relative to Japan, but it's a really important one for us, and it's one where we have great sales execution, great customer relationships, and so we believe in the long-term viability of that market as well.
因此從那個角度看是溫和的,但底層的市場活動其實很強。而且我們沒有任何理由認為這會改變。韓國目前有點處於淡季。韓國相較日本是較小的市場,但對我們非常重要;我們在那裡有很好的銷售執行、很好的客戶關係,因此我們也相信該市場的長期可行性。
India is really, really a long-term play for us. That's a complicated market. It's complicated relative to local competition. It's complicated relative to macroeconomic factors that they're facing. Obviously, there's currency issues associated with being able to access US-made and Swiss-made products in India. So that's a long term process for us, but it's still a really important market.
印度對我們而言真的是非常長期的布局。那是一個複雜的市場。相對於本地競爭,它很複雜。相對於他們所面臨的總體經濟因素,它也很複雜。顯然,在印度取得美國製與瑞士製產品,會伴隨匯率相關的問題。所以這對我們而言是一個長期的過程,但它仍然是一個非常重要的市場。
So as far as the heart of your question of what should we expect as far as growth rate, can't say, but what I would say is we don't have any reason to believe that the viability of EVO in those markets is going to be under any siege.
所以就你問題的核心——我們應該期待怎樣的成長率——我無法給出明確說法;但我想說的是,我們沒有任何理由相信 EVO 在那些市場的可行性會受到任何威脅。
Deborah Andrews - Interim Co-Chief Executive Officer, Chief Financial Officer
Deborah Andrews - Interim Co-Chief Executive Officer, Chief Financial Officer
No, I just wanted to add that plus we're seeing really strong growth in Taiwan, which we just launched last year. And that market is really doing very, very well. Sequentially, every quarter, it's increased significantly. So nice market there.
不,我只是想補充一下:我們也看到台灣有非常強勁的成長,我們是去年才在那裡上市。而那個市場表現非常、非常好。以季度序列(sequentially)來看,每一季都顯著增加。所以那是一個很不錯的市場。
Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer
Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer
It's a fun market to think about because we just got the approval for EVO Plus. It's adjacent to China, obviously. So from a patient population standpoint, they have access and visibility to seeing the social media and the happiness with EVO. One that we're going to start servicing and it's filled with lasers and opportunity.
這是一個很有趣、值得思考的市場,因為我們剛剛拿到 EVO Plus 的核准。它顯然與中國相鄰。因此就患者族群而言,他們能接觸並看到社群媒體上對 EVO 的分享與滿意度。這是我們即將開始服務的一個市場,而且那裡充滿了雷射設備與機會。
Operator
Operator
Ryan Zimmerman, BTIG.
Ryan Zimmerman,BTIG。
Ryan Zimmerman - Analyst
Ryan Zimmerman - Analyst
You know, the first question, I want to go back to the pricing and volume dynamics in China for a minute here. You know, Warren, I was struck by your comments about a third of the lenses in China are EVO Plus. And, you know, let's assume that, you know, there's a 30%, 40% price premium on that product. I mean, that would suggest, I think, that you're getting about, call it 10 points of growth on those lenses.
你知道,第一個問題,我想先回到中國的定價與銷量動態來談一下。你知道,Warren,你提到中國大約三分之一的晶體是 EVO Plus,這點讓我印象深刻。而且,你知道,假設該產品有 30%、40% 的價格溢價。我的意思是,這似乎表示,我認為你在那些晶體上大概獲得了約 10 個百分點的成長。
But if you back that out and all else being equal, if the China market's mid-single digits, is it â and again, I can appreciate that you're taking share in the market, but wouldn't that suggest that the volume, the units are declining in China?
但如果把這個因素扣除、且其他條件都相同的話,如果中國市場是中個位數成長,那是否意味著——而且我也理解你正在提升市占——但這是否表示中國的量、也就是出貨單位數正在下滑?
Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer
Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer
Well, you got to start with this exit share in July. So we don't have, it's not a third of the units of EVO Plus for the full year. And so, remember, we're building as we go. We're not even launched with EVO Plus and all of the hospitals or the systems that we're going to ultimately get launched and listed into. So the math becomes a little bit challenging from that perspective.
嗯,你得先從 7 月的期末市占來看。所以我們並不是整年度 EVO Plus 的單位數有三分之一。因此,記住,我們是邊做邊建立。我們甚至還沒有在所有最終會上市並完成上架/納入名錄的醫院或體系全面推出 EVO Plus。所以從這個角度來看,這個數學推算會有點困難。
But again, I'll just double down on revenue in China now is being driven by two things. It's being driven by return of our EVO V4c, somewhat of a halo effect, and it's being driven by adoption, both units and price, with EVO. And so, How much that's ultimately going to go from a third exit to the full year, we'll see. It remains to be seen, and we have to be able to supply it as well.
但再說一次,我要強調的是,目前中國的營收是由兩件事驅動。一是我們 EVO V4c 的回歸,帶來某種光環效應;二是 EVO 的採用提升,包含單位數與價格兩方面。因此,最終從期末三分之一推到全年會是多少,我們再看。這還有待觀察,而且我們也必須能夠供貨。
Ryan Zimmerman - Analyst
Ryan Zimmerman - Analyst
Okay, that's very helpful and that, you know, buttons that up. The other question I had was just U and, again, I can appreciate, you know, that this is still building, but if you go back to the launch of EVO in the US, I mean, we have seen sequential growth from 1Q to 2Q every quarter since EVO launched.
好的,這非常有幫助,也把這點釐清了。我另一個問題是關於美國市場,而且我也理解這仍在建立中,但如果回到 EVO 在美國上市之初,我的意思是,自從 EVO 上市以來,我們每一季都看到從第一季到第二季的逐季成長。
I appreciate that, you know, it's holding steady at $6 million, but it did decline sequentially a little bit in the US in 2Q. And that may just be, you know, based on small numbers and so forth. But I wanted to at least, you know, get your perspective on that because it is still early days, you know, given the opportunity in the US.
我理解目前維持在 600 萬美元左右,但在第二季美國的數字確實較前一季小幅下滑。而這可能只是因為基期小等等因素。但我至少想聽聽你的看法,因為考量美國的機會,現在仍屬早期階段。
Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer
Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer
That's a good one. Look, I think the long-term value of the US market is massive. I think access that we have is going to create a channel for us to do all sorts of things. And this is a long-term discussion, not a quarter-to-quarter one. But just as a practical matter, even though we do better than the laser market, there's often an inverse relationship between how the laser market declines and we grow, but we're not taking every one of those points of their decline clearly.
這是個好問題。你看,我認為美國市場的長期價值非常巨大。我認為我們所取得的准入將為我們建立一個通路,讓我們能做各式各樣的事情。而這是一個長期的討論,不是逐季的討論。但就實務面而言,即便我們表現優於雷射市場,雷射市場下滑與我們成長之間常常呈現反向關係,但顯然我們並沒有把他們下滑的每一個百分點都完全吃下來。
And so when the overall refractive market shrinks or grows, we benefit from that or we suffer a bit from that. So in Q2, sequentially versus Q1, you saw the laser, the total refractive market go down, driven by lasers because they have the predominant share, And so we suffered a bit from that. So that explains, I think, some of the sequential, we grew but the decline versus our first-quarter performance, which was like 22%.
因此,當整體屈光市場萎縮或成長時,我們會因此受益或也會因此受到一些影響。所以在第二季,相較第一季的逐季變化,你看到雷射帶動的整體屈光市場下滑,因為雷射占比最高;因此我們也受到一些影響。所以我認為這解釋了部分逐季的情況:我們仍在成長,但相較第一季的表現(大約 22%)是有所回落。
There's probably some timing in there also. And then the other thing I'll say candidly, the US makes up 5%, maybe 7% of the share here. When we're on backorder or supply constraint in our largest market, China, or in other markets as a result, as we try and satisfy by building product, we have to build MTOs, made-to-order products for Torics. And when we do that, those are built in smaller units, smaller volume of units, and therefore it gums up our supply chain. And when that happens, guess what?
其中可能也有一些時點因素。另外我也坦白說,美國在這裡的占比只有 5%,也許 7%。當我們在最大市場中國出現缺貨或供應受限,或因為其他市場的需求而我們試圖透過增加產量來滿足時,我們必須生產 MTO(按單生產)的散光片產品。而當我們這麼做時,這些產品是以較小批量、較小單位數生產,因此會卡住我們的供應鏈。而當這種情況發生時,你猜怎麼著?
The US goes on back order for MTOs. And so that's going to explain some of it too. I suspect if you channel check, you'll find some unhappy customers, unfortunately, in the US that are trying to get product from us, which we are cranking out now to try and get caught up.
美國的 MTO 也會進入缺貨待交狀態。所以這也會解釋其中一部分。我猜如果你去做通路查核,你會發現美國有些客戶不太高興,因為他們正試著向我們拿貨;很遺憾,我們現在正在加緊生產,努力把積壓補上。
Operator
Operator
David Saxon, Needham and Co.
David Saxon,Needham and Co.(尼德漢公司)。
David Saxon - Equity Analyst
David Saxon - Equity Analyst
Maybe just on the, I'll start on the ERP, any way to quantify the impact of the second-quarter earnings, I'm sorry, orders or revenue, and does that all get recouped in the third-quarter or does that take longer or is it just lost sales at this point?
我先從 ERP 談起,有沒有辦法量化第二季對獲利——抱歉,是對訂單或營收的影響?而且這些影響是否會在第三季全部補回?還是需要更久?或者到目前為止就只是流失的銷售?
Deborah Andrews - Interim Co-Chief Executive Officer, Chief Financial Officer
Deborah Andrews - Interim Co-Chief Executive Officer, Chief Financial Officer
No, no, we don't think the impact was material, there was any material impact overall on our revenue numbers. You know, as far as the P&L is concerned, the impact was mainly on expenses as we work to stabilize the system overall and upgrade or update the system.
不,不,我們不認為這個影響是重大的,整體而言對我們的營收數字沒有任何重大影響。你知道,就損益表(P&L)而言,影響主要在費用端,因為我們在努力讓系統整體穩定,並進行升級或更新。
But on the revenue side, could there have been some lost sales, I guess, on the MTO side of it, the made-to-order lens side of it? It could have been. But that's mainly driven not by the ERP system. It's driven by the strong demand in the first half of the year, especially in China.
但在營收端,我想,MTO 這一塊——也就是按單生產晶體這一塊——是否可能有一些流失的銷售?有可能。但那主要不是 ERP 系統造成的。而是上半年需求強勁所驅動,尤其是在中國。
Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer
Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer
Hey, David, we referenced it in the pre-release, and then we referenced it in the shareholder letter. Honestly, it's more of an acknowledgment of how hard our teams work because despite the internal that it created, we were still shipping products, still booking orders, still servicing our customers, still delivering the revenue for the quarter, which delivered our profit. So I think the ERP system has been a big lift. We'll continue to tune it as we go, but from a revenue impact, I think it was negligible.
David,我們在預先發布中提到過,也在股東信中提到過。老實說,這更像是對我們團隊辛勞的肯定,因為儘管它在內部造成了(一些)混亂,我們仍然在出貨、仍然在接單、仍然在服務客戶、仍然在交付本季營收,並帶來了本季的利潤。所以我認為 ERP 系統是一項很大的工程。我們會持續邊走邊調整,但就營收影響而言,我認為可以忽略不計。
Deborah Andrews - Interim Co-Chief Executive Officer, Chief Financial Officer
Deborah Andrews - Interim Co-Chief Executive Officer, Chief Financial Officer
Yes, I mean, I would just say, understand that we've actually exceeded our plans, operating plans for both the first and second-quarter of this year. That I will say. we're pleased overall.
是的,我的意思是,我只想說,請理解我們其實在今年第一季與第二季都超越了我們的計畫、營運計畫。這點我可以說。我們整體上很滿意。
David Saxon - Equity Analyst
David Saxon - Equity Analyst
Okay. That's helpful. Thanks for that. And then maybe I'll try a third-quarter question. So obviously appreciate the seasonality commentary. So, I mean, looking at third-quarter, you know, round numbers, sounds like you'll land somewhere in the $70 to $90 million range. I guess sitting here halfway through the quarter or thereabouts, how would you characterize the sequential trend you're seeing? Like how steep or gradual is that trend line looking at this point?
好的。這很有幫助。謝謝你的說明。那我再問一個第三季的問題。所以很明顯也感謝你對季節性的評論。那麼,我的意思是,看第三季,粗略來看,聽起來你們會落在 7,000 萬到 9,000 萬美元的區間。我想問的是,現在坐在這裡、已經過了本季一半左右,你會如何描述你看到的逐季趨勢?就目前來看,那條趨勢線是很陡還是比較平緩?
Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer
Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer
Look, I won't comment on the specifics there. I would just say from a trend line standpoint, I don't think a lot has changed. We've seen some commentary out there around the high season for China, remembering we believe there's kind of two high seasons that happened back to back in Q1 and Q2 now because of the pull forward of the military procedures as well as the Chinese New Year.
你看,我不會對那裡的具體細節做評論。我只會說,就趨勢線而言,我不覺得有太多改變。我們看到外界有一些關於中國旺季的評論;要記得,我們認為因為軍方手術的提前,以及農曆新年因素,第一季和第二季其實出現了某種連續發生的兩個旺季。
And then in the second-quarter, you get a bit of the, to get some of the summer high season, which fades off during Q3. If you listen to what's happening in China, it's sort of flat to mid-single digit sort of growth for the market. And as you've heard us say, at least in the quarter, we've done better than that.
接著在第二季,會受惠於一些夏季旺季的帶動,但這股動能在第三季會逐漸消退。如果你聽聽中國那邊的情況,市場大致是持平到中個位數成長。而且如同你們聽我們說的,至少在本季,我們的表現優於那個水準。
So I all those dynamics hold as we go forward and then you just have to back out the $25.9 million from last quarter to get your Q3 and think about a little bit of growth there. Same for Q4. Q4 was unaffected by that order, but we think we're planning at least to grow in Q4.
所以我認為這些動態在往後仍會延續,然後你只要把上一季的2,590萬美元扣除掉,就能推算你的第三季,並在此基礎上思考會有一些成長。第四季也是一樣。第四季不受那筆訂單影響,但我們的規劃至少是在第四季要成長。
Operator
Operator
Mason Carrico, Stephens.
Mason Carrico,Stephens。
Mason Carrico - Equity Analyst
Mason Carrico - Equity Analyst
Just wanted to ask on ASPs, blended ASPs under pressure from Toric/sphere mix and the diopter curve dynamics. After exiting Q2 at 30% of China volume, is the EVO Plus premium now large enough to offset these headwinds at the consolidated level in the back half of the year?
我想問一下ASP(平均售價)。由於Toric/球面(sphere)產品組合以及屈光度曲線(diopter curve)的動態影響,整體ASP正承受壓力。在第二季結束時EVO Plus已占中國銷量的30%,那麼在今年下半年,EVO Plus的溢價規模是否已大到足以在合併層面抵消這些逆風?
Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer
Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer
I would just say, clearly, we're going to continue to get ASP to the level that we can get it tailwind from EVO Plus. But honestly, price is a function of well at least in Europe, a country like Germany where we have the highest price in Europe, we're facing competition, we're going to have some ASP slippage there, but it's not massive.
我會說,很明顯地,我們會持續把ASP推到能從EVO Plus獲得順風助力的水準。但老實說,價格是一個函數——至少在歐洲,例如德國這種我們在歐洲定價最高的國家,我們正面臨競爭,那裡的ASP會有一些下滑,但幅度不大。
We've held price in most markets around the world partially because the adoption of Toric continues, and so Toric's a little bit higher priced, the higher mix of Toric we have, the better pricing we have, so I'm less concerned about pricing and I'm more concerned and focused on continuing to take share, which we believe we have line of sight to keep doing. So rather than say we're going to overcome price erosion with price in China on EVO Plus, I'd rather say we're focused on taking share on global markets and we think we can do that.
我們在全球多數市場都守住了價格,部分原因是Toric的採用率持續提升,而Toric的價格略高;Toric占比越高,我們的定價就越好,所以我對定價的擔憂較少,反而更關注並聚焦於持續提升市占率,我們相信我們有清晰的能見度可以繼續做到。因此與其說我們要靠中國EVO Plus的價格來克服價格侵蝕,我更願意說我們專注於在全球市場搶市占,我們也認為我們能做到。
You mentioned diopter, and outside of China, if you look at our percentage of units that we sell, if you look at above minus eight and you look at below minus eight , we've moved ourselves down outside of China a couple of percentage points at least down from minus eight into the minus six to minus eight range. And so we believe that we are continuing to move ourselves down the diopter curve. And any time we're doing that, that gives us an opportunity to take share where lasers may have been treating that patient before. And so that's going to be our focus rather than the ASP component.
你提到屈光度。若看中國以外我們銷售的單位占比,若看高於負8與低於負8的區間,我們在中國以外已把占比往下移動了至少幾個百分點,從負8以上移到負6到負8的區間。因此我們相信我們正在持續沿著屈光度曲線往下移動。而每當我們這麼做,就給了我們一個機會去取得原本可能由雷射治療的患者的市占。所以這會是我們的重點,而不是ASP這個面向。
Mason Carrico - Equity Analyst
Mason Carrico - Equity Analyst
Great. Thank you. That all makes sense. And then, sorry if I already missed on the call, but when do you expect to have enough EVO Plus inventory to fully supply the demand you were seeing right now in the China region?
很好。謝謝。這些都很合理。另外,不好意思如果我在電話會議上漏聽了,你們預期何時能有足夠的EVO Plus庫存,來完全滿足目前在中國地區看到的需求?
Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer
Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer
You know, I think we're there or thereabouts now. Remembering that we're going to start to see the summer part of the high season tail off, which gives us a chance to catch our breath and start to build units. So I think by the end of the third-quarter, roughly, we should be in place where we can supply as much EVO Plus as necessary. Now our focus is to build V4c.
你知道,我想我們現在已經差不多到了,或非常接近。要記得,夏季旺季的那一段接下來會開始趨緩,這讓我們有機會喘口氣並開始累積產量。所以我認為大約到第三季末,我們應該就能到位,能供應所需的EVO Plus數量。接下來我們的重點是生產V4c。
Remember, every unit of V4c that we build in Switzerland for China gives us the benefit of not having to pay the tariffs. And so our focus is supplying EVO Plus, but a side card of we want to make sure we supply as much V4c out of China as possible. And we're hoping by the end of the year we're going to be able to accomplish that.
記住,我們在瑞士為中國生產的每一個V4c單位,都能讓我們受益於不必支付關稅。因此我們的重點是供應EVO Plus,但同時也要確保我們能從中國端供應盡可能多的V4c。我們希望在年底前能達成這件事。
Operator
Operator
Adam Maeder, Piper Sandler.
Adam Maeder,Piper Sandler。
Adam Maeder - Senior Research Analyst
Adam Maeder - Senior Research Analyst
I'll keep it to one multi-part question. In the press release, you talked about moving beyond a single product line company into kind of, I think, a true platform was the phrase you used. Could you just expand on that comment? Are you thinking about moving beyond single product line companies the refractive market or is it more a focus of kind of having a broader offering within refractive?
我會把它濃縮成一個多段式問題。在新聞稿中,你們提到要從單一產品線公司,走向某種——我記得你用的詞是——真正的平台。你能否再延伸說明一下這個評論?你們是在思考走出屈光市場、超越單一產品線公司,還是更聚焦於在屈光領域內提供更廣泛的產品組合?
And I'm assuming everything kind of starts and stops with your Collamer-based technology. Is that the right way to think about it? And just any comments around potential timelines, whether it's years or medium, long-term would be helpful.
我假設一切的起點與核心都會是你們以Collamer為基礎的技術。這樣理解對嗎?另外,若能談談可能的時間表——不論是以年計或中長期——都會很有幫助。
Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer
Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer
Thanks Adam. I love the question. Look, we're excited to run this business for the long term. The thinking here now has really evolved to we want to establish the infrastructure and the capabilities for this to be a long-term investment for folks, but a long-term successful company in ophthalmology.
謝謝你,Adam。我很喜歡這個問題。你看,我們很期待以長期的角度來經營這門業務。目前的想法確實已演進為:我們希望建立相關的基礎設施與能力,讓這成為投資人長期投資的標的,同時也成為眼科領域一家長期成功的公司。
And so from a pipeline standpoint, we've got great engineers, and great clinical, medical, regulatory talents in this organization that have been working in the background for years now on a variety of things. And so we're looking forward to bringing those things together in what will be a more cohesive, a more easy-to-understand portfolio. And we'll talk about that in future releases. We're not ready to talk about it today.
因此從研發管線的角度來看,我們組織裡有很棒的工程師,以及優秀的臨床、醫療與法規人才,這些人過去幾年一直在幕後推進各式各樣的項目。所以我們很期待把這些項目整合起來,形成一個更一致、更容易理解的產品組合。我們會在未來的發布中談到這些。今天我們還沒準備好談。
You heard us say we're going to hire a chief technology officer. I'm excited about that. I'm excited to be able to start talking about first in human testing that we will be doing very soon, as early as even the first part of next year, if we can't even do it sooner. And that's on next generation products.
你們也聽到我們說,我們將聘請一位技術長(CTO)。我對此感到很興奮。我也很期待能開始談我們很快就會進行的首次人體試驗(first in human testing),最早甚至可能在明年上半年,如果我們不能更早做的話。而那是針對下一代產品。
We said before we're focused on things, of course, that are going to be very, very important. the material capabilities that we have are unique. And that's how Collamer has differentiated us for many years. So we want to use those same capabilities, whether it's Collamer or whether it's something else, for us to be able to accelerate and become beyond just an EVO ICL company.
我們之前說過,我們聚焦在一些當然會非常、非常重要的事情上。我們所具備的材料能力是獨特的。而這也是Collamer多年來讓我們得以差異化的原因。因此我們希望運用同樣的能力——不論是Collamer或其他材料——來加速發展,讓我們不僅僅是一家EVO ICL公司。
Refractive is our wheelhouse. In the sulcus is our wheelhouse, where the surgeons place the EVO ICL. So I think all of those represent opportunities. You've heard us talk in the past about extended depth of focus or presbyopia correction, being able to take advantage of a patient's natural ability to accommodate, but be able to give them some extra help with a lens-based technology, that's an option amongst many other options. So we'll talk about those in a more formal way as we go, but there's a lot of excitement here about our future.
屈光是我們的主場。睫狀溝(sulcus)也是我們的主場,外科醫師就是把EVO ICL放置在那裡。所以我認為這些都代表著機會。你們過去也聽我們談過延伸景深(extended depth of focus)或老花矯正(presbyopia correction),也就是能利用患者自然的調節能力,同時透過以人工晶體為基礎的技術給予額外的幫助;這是眾多選項之一。所以我們會在推進過程中以更正式的方式談這些,但我們對未來有很多令人振奮的地方。
Adam Maeder - Senior Research Analyst
Adam Maeder - Senior Research Analyst
I'll stay tuned. Thank you.
我會持續關注。謝謝。
Operator
Operator
(Operator instructions).
(接線員指示)。
Showing no further questions, this will conclude our question and answer session as well as conference call. Thank you for attending today's presentation. You may now disconnect.
目前沒有其他提問,本次問答環節以及電話會議到此結束。感謝各位參加今天的簡報。您現在可以掛線。